Pro: ‘Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions’

Andrea Rubboli; Jonathan L. Halperin

doi:10.1160/TH08-05-0334

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 100(05): 752-753
DOI: 10.1160/TH08-05-0334

Pro/Contra Article

Schattauer GmbH

Pro: ‘Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions’

Authors

Andrea Rubboli

¹Division of Cardiology, Cardiac Catheterization Laboratory, Maggiore Hospital, Bologna, Italy
Jonathan L. Halperin

²The Cardiovascular Institute, Mount Sinai Medical Center, New York, New York, USA

Abstract

Full Text

References

References
1 Schlitt A, von Bardeleben RS, Ehrlich A. et al. Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA) . Thromb Res 2003; 109: 131-135.
2 The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006 367. 1903-1912.
3 Rubboli A, Milandri M, Castelvetri C. et al. Metaanalysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology 2005; 104: 101-106.
4 Rubboli A, Halperin JL, Airaksinen KEJ. et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med. 2008 epub ahead of print 1-9.
5 Manzano-Fernàndez S, Pastor FJ, Marìn F. et al. Increased major bleeding complications related to triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest. 2008 July 18; epub ahead of print.
6 Porter A, Konstantino Y, Iakobishvili Z. et al. Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv 2006; 68: 56-61.
7 Ansell J, Hirsh J, Poller L. et al. The pharmacology and management of the vitamin K antagonists. Chest 2004; 126: 204S-233S.
8 Karjalainen PP, Vikman S, Niemelä M. et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J 2008; 29: 1001-1010.
9 Karjalainen PP, Porela P, Ylitalo A. et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007; 28: 726-732.
10 Dahri K, Loewen P. The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules. Thromb Haemost 2007; 98: 980-987.
11 Hughes M, Lip GYH. on behalf of the Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.
12 May AE, Geisler T, Gawaz M. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. Thromb Haemost 2008; 99: 487-493.